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Abstract 
Skeletal muscle is a dynamic tissue capable of responding to a large variety of physiological 
stimuli by adjusting muscle fiber size, metabolism and function. However, in pathological 
conditions such as cancer and neural disorders, this finely regulated homeostasis is impaired 
leading to severe muscle wasting, reduced muscle fiber size (atrophy), and impaired function. 
These disease features develop due to enhanced protein breakdown, which relies on two major 
degradation systems: the ubiquitin-proteasome and the autophagy-lysosome. These systems are 
independently regulated by different signalling pathways, which in physiological conditions, 
determine protein and organelle turnover. However, alterations in one or both systems, as it 
happens in several disorders, leads to enhanced protein breakdown and muscle atrophy. 
Although this is a common feature in the different types of muscle atrophy, the relative 
contribution of each of these systems is still under debate. Here, we will briefly describe the 
regulation and the activity of the ubiquitin-proteasome and the autophagy-lysosome systems 
during muscle wasting. We will then discuss what we know regarding how these pathways are 
involved in cancer induced and in neurogenic muscle atrophy, highlighting common and 
divergent paths.  It is now clear that there is no one unifying common mechanism that can be 
applied to all models of muscle loss. Detailed understanding of the pathways and proteolysis 
mechanisms involved in each model will hopefully help the development of drugs to 
counteract muscle wasting in specific conditions. 
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 Skeletal muscle is a highly dynamic tissue that 
modifies its size to respond and adapt to a large variety 
of stimuli. In physiological conditions, a balance 
between the biosynthetic and catabolic systems 
maintains muscle mass. Stimuli, which alter the 
homeostatic balance determine the predominance of one 
system over the other, leading to either muscle 
hypertrophy or atrophy. Skeletal muscle atrophy occurs 
in a variety of pathological settings, including disuse, 
cachexia, denervation or diabetes and it is characterized 
by a decrease in myofiber size, mainly due to loss of 
organelles, cytoplasm, and proteins, and a reduction in 
muscle function.1 A major contribution in understanding 
muscle atrophy came from studies on gene expression 
profiling performed independently by the groups of 
Goldberg and Glass, in the late 20th century. By 
comparing gene expression profiles in different models 
of muscle atrophy they identified a group of genes that 
are commonly up- or down-regulated in atrophying 
muscle. The commonly up- or down-regulated genes 
were believed to be important for loss of muscle 
components and were called atrophy-related genes or 
“atrogenes”.2,3 Together, these findings marked a major 
advance in the field of muscle wasting and indicated 
that muscle atrophy is an active process controlled by 
specific signalling pathways and transcriptional 
programs. Among the identified genes, several belong 
to the major cellular degradation systems, the ubiquitin-
proteasome (UPS) and the autophagy-lysosome. Both 
were found to be primarily regulated by the 
phosphoinositide 3-phosphate (PI3K)-AKT-mammalian 
target of rapamycin (mTOR) signalling pathway, which 
promotes protein synthesis, while suppressing protein 
degradation, and by the FOXO transcription factors, 
which can directly induce the transcription of both 
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phosphorylation by AKT, FOXO is retained in the 
cytoplasm, and becomes inactive.8 Among the FOXO 
family members, FOXO-1 and -3 appear to be mostly 
involved in muscle wasting, since they are activated in 
all types of atrophy and both induce members of the 
UPS and autophagy machineries. Their activity is 
tightly regulated at post-transcriptional level: 
phosphorylation by AKT, deacetylation by sirtuin1, 
ubiquitylation, or binding to JunB or to PGC1α inhibits 
FOXO3 activity, preventing muscle wasting.4,9–13 On the 
other hand, phosphorylation by mammalian sterile 20-
like protein-1 (MST1) or 5’-AMP activated protein 
kinase (AMPK) activates FOXO-3, and promotes 
proteolysis and muscle wasting.14–16 Another member of 
this family, FOXO-4, appears to mediate TNFα-induced 
atrophy-related gene expression, in an AKT-
independent manner.17 Interestingly, a recent study 
proposes that FOXO-4 activity is regulated by the With-
no-lysine (K) (WNK) kinase-1, instead, and that a 
WNK1-FOXO-4 axis is involved in the physiological 
regulation of skeletal muscle mass maintenance.18 Other 
transcription factors can also be important in causing 
muscle atrophy in specific settings, including SMAD-2 
and -3, glucocorticoid receptors, and Nuclear Factor-κB 
(NFκB), whose inhibition can reduce or block different 
types of atrophy.8,19–22 The precise roles of these 
transcription factors in regulating the expression of 
muscle atrophy-related genes is still unclear, but it 
appears that they cooperate with or act on FOXO- 
transcription factors, the principal mediators of muscle 
atrophy.  
Although it is now clear that the activation of 
“atrogenes” leads to protein breakdown, the pathways 
activated, and in turn, the specificity of the downstream 
targets might be different in different settings. Below 
we discuss the possible similarities and differences 
between cancer-induced and neurogenic muscle 
atrophy, focussing on the UPS and autophagy systems.  
Cancer-induced cachexia is a complex, systemic, 
metabolic syndrome characterized by severe muscle 
loss. Pro-inflammatory cytokines, such as TNFα, IL1β 
and IL6, contribute to muscle wasting and protein 
breakdown, acting either directly or systemically. On 
the other hand, neurogenic muscle atrophy might 
develop primarily due to the disruption of the NMJ-
dependent signalling pathways required for muscle 
maintenance.23–27 One similarity is that both cancer-
induced and neurogenic muscle atrophy, are associated 
with increased UPS and autophagy activity. However, 
the specificity and the relative contribution of 
downstream targets in the resulting muscle loss in these 
different settings, is still unclear. 
The Ubiquitin-proteasome system in cancer-induced 
and in neurogenic muscle atrophy 
The UPS is one of the major systems governing protein 
degradation, and, in physiological conditions, ensures 
protein turnover and quality control. Degradation 
requires tagging of the protein by covalent binding to 
the multiple ubiquitin molecules, and breakdown of the 
tagged substrate by the 26S proteasome. This process 
involves at least three classes of enzymes: the ubiquitin-
activating E1, the ubiquitin-conjugating E2 and the 
ubiquitin-ligase E3. The major muscle-specific 
members of the ubiquitin machinery first identified as 
consistently increased in muscle atrophy were atrogin-
1/MAFbx and MuRF1, belonging to the E3 class of 
ubiquitin-ligases.2,28 These enzymes are strongly up-
regulated in a wide range of conditions associated with 
muscle wasting, including cancer, diabetes, 
glucocorticoid or cytokine treatments as well as in 
denervation. Several studies suggest that, while 
numerous stimuli can activate both atrogin-1 and 
MuRF-1, the downstream pathways affected may be 
different for each protein. For example, MyoD appears 
to be a preferential substrate of atrogin-1.29 When 
atrogin-1 was overexpressed, polyubiquitination of 
MyoD was observed, while knock-down of atrogin-1 
reversed endogenous MyoD degradation; moreover, the 
expression of a MyoD mutant resistant to ubiquination, 
prevented muscle atrophy in vivo.30 Furthermore, 
Atrogin-1 was found to interact with transcription 
factors, components of the translational machinery, 
soluble enzymes, mitochondrial proteins, as well as with 
sarcomeric proteins, including myosins, desmin and 
vimentin.31 On the other hand, MuRF-1 mainly interacts 
with structural proteins such as myosin heavy chain 
proteins.32,33 Additionally, MuRF-1 degrades myosin 
light chain 1 and 2 during denervation and fasting 
conditions.34 Several studies using tumour-bearing 
animal models have suggested that accelerated 
proteolysis and muscle wasting in cancer cachexia is 
mainly due to the up-regulation of members of the 
proteasome subunits expression, increased UPS activity, 
as well as the overexpression of both atrogin-1 and 
MuRF-1.35–38 
Proinflammatory cytokines, such as TNFα can induce 
the expression of genes involved in UPS activity, and 
knockdown of atrogin-1 by small interfering RNA 
(siRNA) protected C2C12 muscle cells from the adverse 
effect of TNF-α.38 Another signalling pathway 
suggested to be involved is the Akt. It has been shown 
that cachexia-associated loss of Akt-dependent 
signalling in human skeletal muscle was associated with 
decreased activity of regulators of protein synthesis and 
a disinhibition of protein degradation.39 Indeed, FoxO-
dependent transcription appears to play a central role in 
controlling diverse gene networks in skeletal muscle 
during cancer cachexia, since its inhibition prevented 
muscle atrophy in a tumour-bearing mouse model.40 
Moreover, transcriptome analysis of upregulated gene 
transcripts that required FoxO, revealed enrichment of 
the proteasome, AP-1 and IL-6 pathways, and included 
several atrophy-related transcription factors.41 In 
cachectic tumour-bearing mice, circulating IL-6 levels 
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and mTORC1 signalling.42 Indeed, it was reported that 
salidroside, a phenylpropanoid glycoside in 
Rhodiolarosea L, alleviates cancer cachexia symptoms 
via activation of the mTOR signalling, and prevents 
TNFα-induced down-regulation of mTOR in C2C12 
cells,43 suggesting that promoting mTOR signalling and 
ribosomes biogenesis counteracts cancer-induced 
muscle atrophy. However, investigations in humans 
have so far failed to be conclusive, and results on the 
level of UPS activity in different type of cancer patients 
have been contradictory.44–47 The likely reason for the 
conflicting findings could be the fact that the kinetics of 
cancer development and signalling in humans are 
different compared to mice.  
In contrast, during denervation, the mTOR pathway was 
unexpectedly found to be activated, and the expression 
of genes related to myogenesis were markedly 
increased, while that of myostatin, a known muscle 
growth inhibitor, was decreased.48 However, de novo 
ribosomal RNA synthesis and the levels of ribosomal 
RNAs were dramatically decreased in denervated 
muscle, suggesting that ribosome biogenesis is strongly 
controlled by factors other than the mTOR pathway. On 
the other hand, denervation atrophy was not protected 
by ActRIIB treatment, yet resulted in an upregulation of 
the pro-growth factors AKT, SGK and components of 
the mTOR pathway. Thus, these studies suggested that 
denervation atrophy is not only independent from AKT, 
SGK and mTOR activation, but also has a different 
underlying pathophysiological mechanism compared to 
other types of muscle atrophy.49 
Despite the recognized role of the Atrogin-1 and MuRF-
1 E3 ligases in muscle atrophy, there is as yet no 
evidence suggesting their requirement in animal models 
of cancer cachexia. On the other hand, their role in 
neurogenic muscle atrophy, was previously explored by 
Moresi V et al, showing an up-regulation of Atrogin-1 
and MuRF-1 in muscle upon denervation, via up-
regulation of myogenin expression.50 By preventing the 
denervation-dependent induction of myogenin 
expression, up-regulation of Atrogin-1 and MuRF-1 was 
also prevented and muscle loss counteracted, 
highlighting a crucial role of these enzymes in 
neurogenic muscle atrophy. However, atrogin-1/MAFbx 
or MuRF1knockout mice are only partially resistant to 
denervation-induced atrophy. Together, these data 
suggest either that the expression of one of these ligases 
is enough to induce neurogenic muscle atrophy, or that 
additional factors are required to mediate denervation-
induced muscle loss. Also, in other types of muscle 
atrophy models, such as fasting or glucocorticoid 
treatment, targeting one or the other E3 ligases, either 
genetically or pharmacologically, were not conclusive, 
arguing against the exclusive role of these enzymes in 
muscle loss.51–53 These observations prompted 
researchers to search for other ubiquitin ligases that 
contribute to sarcomeric protein breakdown. Among 
them TRAF6, another E3 ligase, was identified. 
Interestingly, muscle-specific TRAF6 knock out mice 
are resistant to muscle loss induced by either 
denervation, cancer or starvation.54–56 This protection 
appears to depend on both direct and indirect effects on 
protein breakdown. Another novel ubiquitin ligase 
MUSA-1 belongs to the SCF complex, and its 
expression is highly induced in a tumour-bearing mouse 
model. While there is no direct evidence for its role in 
cancer-mediated muscle loss, its knockdown by RNA 
interference significantly reduced neurogenic muscle 
atrophy.53 In addition to the ubiquitin ligases, several 
proteasome subunits, as well as some de-ubiquinating 
enzymes, have been shown to be strongly upregulated in 
muscle during cancer cachexia and/or denervation,57,58 
however their contribution to muscle atrophy is still 
under investigation, and will not be discussed here. 
The autophagy-lysosome system in cancer-induced 
and in neurogenic muscle atrophy 
The other major proteolytic system involved in muscle 
atrophy is the autophagy-lysosome system. In the 
autophagy system, small ubiquitin-like molecules (LC3, 
GABARAP, GATE16, and Atg7) are transferred from 
the conjugation system to membranes which then grow 
and commit to become a double-membrane vesicle 
(autophagosome) that engulfs portions of the cytoplasm 
leading to the proteolysis of long-lived proteins and 
organelles.59 In contrast to the proteasome-ubiquitin E3 
ligases or “atrogenes”, discussed above, whose 
expression is clearly induced to initiate the atrophy 
program, whether and to what extent autophagy 
contributes to muscle loss in different conditions, is not 
clear yet. Autophagy, also referred as macroautophagy, 
is an important physiologic mechanism that ensures 
recycling of damaged organelles and macromolecules, 
thus maintaining tissue homeostasis. It is therefore 
conceivable that alterations in autophagy, either an 
increase or a decrease, can exacerbate muscle loss 
during catabolic conditions. The activation of autophagy 
was initially regarded as one of the catalytic 
mechanisms leading to muscle atrophy in several 
conditions, such as cancer cachexia, starvation, disuse 
and denervation.27,60–62 However, reduced autophagy 
was also associated with some muscle disorders, such as 
the UCMD and Bethlem myopathies or the Duchenne 
muscular Dystrophy, as well as sarcopenia.63–66 Indeed, 
treatment with chloroquine, a lysosome inhibitor, 
induced a severe myopathy (e.g., chloroquine 
myopathy) due to generalized lysosome impairment. 
Similarly, mouse models lacking Atg5 or Atg7, or with 
compromised autophagy, undergo generalized myofiber 
degeneration due to accumulation of protein aggregates, 
appearance of abnormal mitochondria, induction of 
oxidative stress, and activation of unfolded protein 
response.67,68 Re-activation of autophagy, through low-
protein diet, counteracted muscle defects in both animal 
models and patients, highlighting the important role of 
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The autophagy machinery in muscle atrophy, like the 
proteasome system, is controlled by the FoxO protein 
family, predominantly by the FoxO3 member.6,68,70,71 
FoxO3 activation increases the expression of many 
autophagy-related genes in myotubes, and its 
inactivation is incompletely compensated by the other 
factors in preventing muscle loss, suggesting that 
FoxO3 is the most critical factor for the atrophy 
programme. Interestingly, FoxOs inhibition did not 
result in severe myopathy, unlike chloroquine treatment 
or Atg7 depletion, suggesting that FoxOs acts electively 
on the autophagy-induced muscle atrophy program.68 
This finding implies the existence of a subset of FoxO-
dependent downstream targets regulating autophagy in 
muscle wasting, without interfering with the 
physiological clearance. The identification of those 
targets will no doubt be useful for the design of novel 
strategies aiming to selectively prevent autophagy-
dependent muscle loss in specific settings. Although 
speculative at this stage, the FoxO-dependent 
downstream targets could be different depending on the 
stimulus. Since FoxO factors do not act alone to induce 
atrophy related genes, but cooperate with other factors, 
such as NFκB, SMADs etc, which might be activated in 
response to a specific atrophy stimulus, this possibility 
is very likely. Intriguingly, the lists of FoxO-dependent 
genes during denervation and fasting do not overlap 
completely68. Studies on the molecular pathways 
involved in neurogenic muscle atrophy and on the 
contribution of the autophagy machinery in this setting, 
have produced conflicting results. Some studies 
reported that autophagy is suppressed in muscle early 
after denervation.72 while, according to others, it is 
triggered seven days after denervation, primarily 
targeting damaged mitochondria,73,74 Other studies 
reported the activation of autophagy markers three days 
after denervation, as a possible mechanism leading to 
muscle wasting.68 However, in contrast to fasting, 
deletion of FoxO 1,2,3 only partially prevented 
neurogenic muscle atrophy and the autophagy system 
was mildly affected.68 Interestingly, exercise, known to 
induce autophagy in muscle, was recently found to 
prevent neurogenic muscle atrophy, maintaining 
proteostasis in muscle.75,76 So far, none of the above 
studies conclusively determined whether autophagy 
contributes to neurogenic muscle atrophy or not. To this 
end, a recent study by the group of Moresi, published in 
the previous issue of EJTM, addressed this question 
more closely.77 They found that the expression of 
autophagy markers is induced as early as eight hours 
following denervation and increased over time. The 
observed increase appeared to be independent from 
FoxO activation.68,77 Indeed, both Akt and mTOR 
active/phosphorylated forms were higher in denervated 
muscle after 7 days, compared to control muscle. As 
mentioned before, Akt is known to promote protein 
synthesis, and its activation in this setting might reflect 
an attempt to counteract muscle loss; on the other hand, 
the denervation-induced mTOR activity may counteract 
Akt pathway activation, or even increase proteasome 
level, as previously suggested.78,79 Interestingly, since 
mTOR is known to inhibit autophagy, its activation in 
denervated muscle suggests that it has no major effect 
on autophagy in neurogenic muscle atrophy, in contrast 
to muscle atrophy driven by other stimuli.  Despite the 
signalling pathways involved in autophagy activation 
during denervation, whether autophagy contributes to 
neurogenic muscle atrophy is still unclear. Interestingly, 
Pigna et al. showed that further inducing autophagy 
following denervation, by either intermittent fasting or 
rapamycin treatment, did not alter denervation-induced 
muscle atrophy. Conversely, Tang et al. showed that 
treatment with higher doses of rapamycin prevented 
muscle atrophy, mostly by preventing E3-ubiquitin 
ligases upregulation, in a FOXO-dependent manner. 
Indeed, rapamycin treatment of mice restored Akt 
activity, suggesting that the denervation-induced 
increase in mTORC1 activity was producing a feedback 
inhibition of Akt. To further complicate the story, 
autophagy was shown to be rather suppressed in 
denervated muscles, due to a constitutive activation of 
mTORC1.72 Further studies are needed to conclusively 
understand whether and, at which stage of the process, 
autophagy is required for neurogenic muscle atrophy.  
Likewise, whether and how autophagy can contribute to 
cancer-induced muscle atrophy is also controversial. As 
mentioned above, autophagy was found to be activated 
in cachectic muscle.47,80–83 Nevertheless, although acute 
systemic inhibition of autophagy in tumour-bearing 
mice significantly ameliorated tumour growth, it failed 
to prevent muscle and fat loss, suggesting that 
autophagy is required for muscle maintenance.84,85 It is 
important to stress here that cancer cachexia is a 
systemic multifactorial disorder, and autophagy 
activation in muscle could be required as a metabolic 
response to inflammatory, nutritional or energy stresses 
induced by tumour growth. Interestingly, exercise has 
emerged as a possible therapeutic strategy to counteract 
cancer cachexia and prolong life span in cancer 
patients.85–88 Exercise is known to physiologically 
activate autophagy in muscle, which appears to mediate 
the beneficial effects of physical activity on glucose 
homeostasis.62,89,90 Together, these data suggest that 
systemic activation of autophagy might preserve tumour 
cell survival, and its inhibition may reduce tumour 
growth; at the same time, autophagy is required in 
muscle to ensure clearance of dysfunctional organelles, 
and thus maintain energy homeostasis. 
Conclusions and Perspectives 
Significant advances have been made during the past 
decade in our understanding of the mechanisms that 
control muscle wasting. A major breakthrough has been 
the identification of the ubiquitin proteasome and 
autophagy lysosome systems, as the principal cellular 
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muscle, and the transduction pathways controlling their 
activity. However, it is now clear that, although very 
similar, there is no common mechanism that applies to 
all models of muscle wasting.  As discussed above, 
activation of the UPS system appears a common feature 
in both cancer-induced or in neurogenic muscle atrophy, 
although specific downstream targets might differ, and 
still need to be conclusively identified. Moreover, while 
autophagy is emerging as a selective degradation 
system, given the conflicting findings thus far, studying 
the degraded proteins or organelles of the autophagic 
process as wells as the kinetics of their disposal would 
be more informative. 
In summary, a more detailed understanding of the 
relative contribution of the degradative systems and the 
downstream targets involved in cancer-induced or in 
neurogenic muscle atrophy is needed to facilitate the 
development of novel therapeutics for the prevention of 
muscle loss. 
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